Please login to the form below

Not currently logged in
Email:
Password:

FDA accepts Wyeth's Tygacil sNDA for review

US-based Wyeth Pharmaceuticals has reported that the FDA accepted its supplemental new drug application (sNDA) for first-in-class antibiotic Tygacil (tigecycline) for the treatment of patients with community-acquired pneumonia.

US-based Wyeth Pharmaceuticals has reported that the FDA accepted its supplemental new drug application (sNDA) for first-in-class antibiotic Tygacil (tigecycline) for the treatment of patients with community-acquired pneumonia.

The agency will complete its review of the application and may approve or disapprove the application, request additional data or take other administrative actions.

The sNDA submission included integrated data from two investigational clinical studies involving 846 patients. Study data showed that Tygacil cured 89.7 per cent of patients hospitalised with community-acquired pneumonia (CAP), and levofloxacin, an existing treatment option for CAP, cured 86.3 per cent of studied patients.

The most common adverse events for Tygacil were nausea, vomiting and abdominal pain. The discontinuation rates due to adverse events for Tygacil and levofloxacin were similar, 6.1 per cent and 8.3 per cent, respectively.

The FDA approved Tygacil in June 2005 for use in hospital patients with serious bacterial infections, including those
resistant to most other antibiotics. The intravenous drug is used as a first-line treatment for stomach and skin infections and is effective against enough different bacteria to be used before doctors know which ones are causing the infection.

Gary Stiles, Wyeth's CMO, said: "Community-acquired pneumonia is a serious respiratory disease that affects millions of Americans. The acceptance of this sNDA is an important event as it brings Wyeth closer to providing physicians with a new option for the treatment of CAP."

For Q3 FY07, Wyeth said that Tygacil hit the USD 100m mark and added that it was on track to meet its goal of doubling FY06 revenues, driven by US growth.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

AstraZeneca’s oncology renaissance
Susan Galbraith played a key role in restoring AstraZeneca’s place in cancer drug development – she talks about the future of oncology and why there’s more to be done to...
Navigating the antibiotic resistance crisis
Blue Latitude Health speaks to Tara DeBoer, PhD, Postdoctoral Researcher and CEO of BioAmp Diagnostics to explore the antimicrobial resistance crisis, and learn how a simple tool could support physicians...
Combined immunotherapies – potential and pitfalls
‘Combining therapeutic compounds is the first logical step towards better results, namely higher rates of patients responding to treatment, with deeper and more sustained responses’...

Infographics